RANI Stock Analysis: Buy, Sell, or Hold?
RANI - Rani Therapeutics Holdings, Inc. Class A Common Stock
$1.10
0.05 (4.76%)
▲
5d:
+18.15%
30d:
+14.58%
90d:
-12.0%
HOLD
MODERATE Confidence
Analysis Updated: May 13, 2026 12:00 AM ET
Earnings: May 12, 2026
0d
Smart Money Distribution
RANI is up 4.9% this week, but smart money is buying puts. Top strike: $0.5 2026-07-17 with 17 OI. Put ratio: 100% View Scanner →
Strength: 7.4/10
Get Alerted When RANI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called RANI this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: RANI is 8.9% above its trading range ($1.01). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: RANI is 8.9% above its trading range ($1.01). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: RANI is currently trading at $1.10, which is considered extended relative to its 30-day fair value range of $0.83 to $1.01.
Technical Outlook: Technically, RANI is in a strong downtrend. The price is approaching resistance at $1.12. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.8% recently.
Market Sentiment: RANI has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $7.40 (+604.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, RANI is in a strong downtrend. The price is approaching resistance at $1.12. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.8% recently.
Market Sentiment: RANI has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $7.40 (+604.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.83 -
$1.01
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range (+8.9% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.8%)
- BULLISH: Trading 604.8% below Wall St target ($7.40)
- CAUTION: Extended 8.9% above its trading range - wait for pullback
Trading Range Analysis
30-Day Trading Range
$0.83 -
$1.01
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.87
Resistance Level
$1.12
Current Trend
Strong Downtrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.61
Wall Street Target
$7.40
(+604.8%)
Revenue Growth (YoY)
42.1%
Share & Embed Analysis
Last updated: May 14, 2026 1:36 PM ET
Data refreshes hourly during market hours. Next update: 2:36 PM
Data refreshes hourly during market hours. Next update: 2:36 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RANI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 60 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$104 | 59 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 57 HOLD |
|
BHVN
Biohaven Pharmaceutical … |
STRONG BUY
16 analysts |
$22 | 57 HOLD |
